Where are the top Big Pharma hubs in 2023?

By analyzing the financials of dozens of Big Pharma firms, we can pinpoint the global hubs that drive much of the industry’s innovation. This analysis reveals regions like New York, New Jersey, Tokyo, Basel, and Frankfurt metro area as core centers for pharma revenue and R&D spending. Unsurprisingly, the area with the densest concentration of top pharma hubs is the Northeast, including the states of New Jersey, New York, and Massachusetts. While the U.S. dominates in terms of the sheer number of Big Pharma giants, Europe holds its own, with Switzerland, the United Kingdom, France, and Germany each hosting multiple companies generating tens of billions in annual revenue. In Asia, Japan and India are significant players in the global pharma landscape, with companies in Tokyo and Hyderabad well represented.

See the map below for an overview of where the world’s 50 top pharmaceutical companies and corresponding pharma hubs are headquartered, with each firm categorized into one of five tiers based on its 2023 revenue. Larger companies appear in orange and red:

By analyzing the concentration of pharmaceutical companies and their revenues, we can identify the largest global hubs. Below are the top 10 Big Pharma hubs based on Big Pharma company density and revenue within each region.

Switzerland: The Alpine pharma powerhouse

• Total R&D Spending: $28.41B
• Total Revenue: $100.15 billion
• Notable Players: Roche Pharmaceuticals (Basel; $49.64B) and Novartis (Basel; $45.44B). Abbott's legacy pharma business is also located in Basel.

New Jersey: The Garden State's pharmaceutical greenhouse

• Total R&D Spending: $26.78B
• Total Revenue: $166.14B
• Notable Players: Merck & Co. (Rahway; $60.12B), Johnson & Johnson Innovative Medicine (New Brunswick; $54.76B), Bristol Myers Squibb (Princeton; $45.01B), and Organon (Jersey City; $6.26B). Incidentally, Merck is now the biggest pharma overall by revenue after overtaking Pfizer in 2023.

Japan: The Land of the rising pharma 

• Total R&D Spending: $10.53B
• Total Revenue: $76.62B
• Notable Players: Takeda Pharmaceutical (Tokyo; $28.67B), Astellas Pharma (Tokyo; $10.81B), Daiichi Sankyo (Tokyo; $9.77B), Otsuka Holdings (Tokyo; $9.71B), Chugai (Tokyo; $7.38B), Eisai (Tokyo; $6.03B), and Sumitomo Dainippon Pharma (Osaka; $4.25B)

New York: The Empire State's pharmaceutical empire

• Total R&D Spending: $15.14B
• Total Revenue: $71.62 billion
• Notable Players: Pfizer (New York City; $58.50B) and Regeneron Pharmaceuticals (Tarrytown; $13.12B)

Boston/Cambridge, Massachusetts: The biotech Bay State

• Total R&D Spending: $10.47B
• Total Revenue: $34.03B
• Notable Players: Moderna ($19.30B), Vertex Pharmaceuticals ($9.87B), and Biogen ($9.84B)

Germany: Europe's pharma powerhouse

• Total R&D Spending: $9.08B
• Total Revenue: $58.29B
• Notable Players: Boehringer Ingelheim (Ingelheim am Rhein) ($20.01B), Bayer (Pharmaceuticals Division; Berlin; $19.56B) and BioNTech (Mainz) ($18.72B)

Chicago, Illinois: The Midwestern pharmaceutical anchor

• Total R&D Spending: $7.68B
• Total Revenue: $54.32B
• Notable Players: AbbVie (North Chicago) ($54.32B)

London/Cambridge, UK: The Crown Jewels of British pharma

• Total R&D Spending: $18.68B
• Total Revenue: $83.50B
• Notable Players: AstraZeneca (Cambridge; $45.81B) and GSK (Brentford, U.K.): $37.69 billion

Paris, France: The French pharma sector remains strong

• Total R&D Spending: $7.76B*
• Total Revenue: $67.30B
• Notable Players: Sanofi (Paris; $58.76B) Servier (Suresnes, Paris suburb; $5.27B) and  Ipsen (Boulogne-Billancourt, Paris suburb; $3.27B)

*Note: The total R&D spending does not include Servier's figures, as they were not available when assembling this report.

Note: Since 2023 financial data is not yet available for all companies, 2022 revenue data were used to illustrate the financial performance of the following companies in the map, including Astellas Pharma, Aurobindo Pharma, BioNTech, Boehringer Ingelheim, Daiichi Sankyo, Dr. Reddy's Laboratories , Eisai, Grifols, Ipsen, Menarini, Merck KGaA, Otsuka Holdings, Servier, Sino Biopharmaceutical, Sumitomo Dainippon Pharma, Sun Pharmaceutical Industries, and Takeda.

The feature on top pharma hubs in 2023 will be updated as more data becomes available.

---

Filed Under: Drug Discovery and Development, Pharma 50
Tagged With: global pharma hubs, innovation, pharmaceutical industry, research and development, revenue
 

---